Authorized purpose: Enable visualization and measurement of heart and vessel structures for preprocedural planning and sizing of structural-heart interventions, including LAAO and TAVI; qualified clinicians use the results with clinical history, symptoms, other evaluations, and professional judgment, and the results do not replace implant-device instructions for final device selection or placement.
Clinical role
AI-assisted and human-supervised cardiovascular segmentation, visualization, annotation, and measurement for preprocedural planning and sizing of transcatheter structural-heart interventions; clinicians review and adapt segmentation as needed.
Images and patients
CT/CTA · Heart and cardiovascular vessels, including the left atrium, left atrial appendage, aortic root/ascending aorta, and left ventricle
Key limitation
Keep in mind: The results are for preprocedural planning and sizing and do not replace implant-device instructions for final LAAO or TAVI selection and placement. The subject device lacks the predicate's post-intervention evaluation and coronary-calcification/diagnostic functions. Segmentation is followed by human supervision and quality checking, and the TAVI perimeter-based annulus diameter is not automatically calculated; manual action is required. The service-based cloud workflow's current data flow and security configuration are not established.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Enable visualization and measurement of heart and vessel structures for preprocedural planning and sizing of structural-heart interventions, including LAAO and TAVI; qualified clinicians use the results with clinical history, symptoms, other evaluations, and professional judgment, and the results do not replace implant-device instructions for final device selection or placement.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart and cardiovascular vessels, including the left atrium, left atrial appendage, aortic root/ascending aorta, and left ventricle Input: CT data in DICOM format of the heart and vessels for patients undergoing preprocedural planning for structural-heart interventions, including LAAO and TAVI; the exact acquisition protocol is not specified in the FDA packet.
Who uses it?Intended users: Qualified clinicians, including cardiologists, radiologists, and clinical specialists
What does the software produce?Output: Cardiovascular segmentations, 2D review and MPR, interactive 3D visualizations, landmarks, measurements and annotations, PDF reports, and DICOM MPR visualizations. LAAO output includes mean landing-zone diameter measurements; TAVI output includes a perimeter-based aortic-annulus diameter that requires a manual measurement action. The application can also display output from FEops HEARTguide Simulation Application K214066.
What is its most important limitation?Key limitation: The results are for preprocedural planning and sizing and do not replace implant-device instructions for final LAAO or TAVI selection and placement. The subject device lacks the predicate's post-intervention evaluation and coronary-calcification/diagnostic functions. Segmentation is followed by human supervision and quality checking, and the TAVI perimeter-based annulus diameter is not automatically calculated; manual action is required. The service-based cloud workflow's current data flow and security configuration are not established.
Clinical takeaway. Clinical role: Enable visualization and measurement of heart and vessel structures for preprocedural planning and sizing of structural-heart interventions, including LAAO and TAVI; qualified clinicians use the results with clinical history, symptoms, other evaluations, and professional judgment, and the results do not replace implant-device instructions for final device selection or placement.
Evidence takeaway. Evidence from the reviewed source record: FDA K223855 reports separate retrospective 35-case studies for LAAO and TAVI with no training-data overlap. For LAAO, semi-automatic landing-zone diameter mean difference was 1.4% +/- 4.6% with limits of agreement -7.7% to 10.4% and confidence limits within the prespecified +/-18% goal; semi-automatic LAA-region Dice was 0.98 +/- 0.01. For TAVI, semi-automatic annulus diameter mean difference was 0.5% +/- 1.9% with limits of agreement -3.2% to 4.2% and confidence limits within the prespecified +/-10% goal; semi-automatic aortic-root Dice was 0.97 +/- 0.01. Fully automatic LAAO and TAVI segmentation Dice values were also reported separately, 0.93 +/- 0.04 and 0.96 +/- 0.01 respectively.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Enable visualization and measurement of heart and vessel structures for preprocedural planning and sizing of structural-heart interventions, including LAAO and TAVI; qualified clinicians use the results with clinical history, symptoms, other evaluations, and professional judgment, and the results do not replace implant-device instructions for final device selection or placement.
AI-assisted and human-supervised cardiovascular segmentation, visualization, annotation, and measurement for preprocedural planning and sizing of transcatheter structural-heart interventions; clinicians review and adapt segmentation as needed.
CT data in DICOM format of the heart and vessels for patients undergoing preprocedural planning for structural-heart interventions, including LAAO and TAVI; the exact acquisition protocol is not specified in the FDA packet.
Cardiovascular segmentations, 2D review and MPR, interactive 3D visualizations, landmarks, measurements and annotations, PDF reports, and DICOM MPR visualizations. LAAO output includes mean landing-zone diameter measurements; TAVI output includes a perimeter-based aortic-annulus diameter that requires a manual measurement action. The application can also display output from FEops HEARTguide Simulation Application K214066.
The results are for preprocedural planning and sizing and do not replace implant-device instructions for final LAAO or TAVI selection and placement. The subject device lacks the predicate's post-intervention evaluation and coronary-calcification/diagnostic functions. Segmentation is followed by human supervision and quality checking, and the TAVI perimeter-based annulus diameter is not automatically calculated; manual action is required. The service-based cloud workflow's current data flow and security configuration are not established.
FDA K223855 reports separate retrospective 35-case studies for LAAO and TAVI with no training-data overlap. For LAAO, semi-automatic landing-zone diameter mean difference was 1.4% +/- 4.6% with limits of agreement -7.7% to 10.4% and confidence limits within the prespecified +/-18% goal; semi-automatic LAA-region Dice was 0.98 +/- 0.01. For TAVI, semi-automatic annulus diameter mean difference was 0.5% +/- 1.9% with limits of agreement -3.2% to 4.2% and confidence limits within the prespecified +/-10% goal; semi-automatic aortic-root Dice was 0.97 +/- 0.01. Fully automatic LAAO and TAVI segmentation Dice values were also reported separately, 0.93 +/- 0.04 and 0.96 +/- 0.01 respectively.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA K223855 reports separate retrospective 35-case studies for LAAO and TAVI with no training-data overlap. For LAAO, semi-automatic landing-zone diameter mean difference was 1.4% +/- 4.6% with limits of agreement -7.7% to 10.4% and confidence limits within the prespecified +/-18% goal; semi-automatic LAA-region Dice was 0.98 +/- 0.01. For TAVI, semi-automatic annulus diameter mean difference was 0.5% +/- 1.9% with limits of agreement -3.2% to 4.2% and confidence limits within the prespecified +/-10% goal; semi-automatic aortic-root Dice was 0.97 +/- 0.01. Fully automatic LAAO and TAVI segmentation Dice values were also reported separately, 0.93 +/- 0.04 and 0.96 +/- 0.01 respectively.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
FEops HEARTguideTM, FEops HEARTguideTM ALPACA regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K223855
Samplen=35
IndependenceIndependence not established
K223855
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K223855. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: CT data in DICOM format of the heart and vessels for patients undergoing preprocedural planning for structural-heart interventions, including LAAO and TAVI; the exact acquisition protocol is not specified in the FDA packet.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The FDA packet describes a service-based cloud workflow, CT DICOM input, a web application, PDF reports, interactive 3D, and DICOM MPR outputs; the customer provides input data and FEops prepares and returns the anatomical analysis. Specific current PACS, RIS, EHR, interfaces, versions, hosting region, and local deployment are not established.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes FEops HEARTguide ALPACA as a cloud-based device used in a service-based model in which FEops prepares the anatomical analysis and delivers results to clinicians through its web application. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Cloud-based Yes No, 3mensio is a Different, while the traditional software subject device is cloud-" … "The software is used in a service-based business model: the customer (clinician) provides the necessary input data, FEops prepares the anatomical analysis, and delivers the results to the customer.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Cardiovascular segmentations, 2D review and MPR, interactive 3D visualizations, landmarks, measurements and annotations, PDF reports, and DICOM MPR visualizations. LAAO output includes mean landing-zone diameter measurements; TAVI output includes a perimeter-based aortic-annulus diameter that requires a manual measurement action. The application can also display output from FEops HEARTguide Simulation Application K214066.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Cardiovascular segmentations, 2D review and MPR, interactive 3D visualizations, landmarks, measurements and annotations, PDF reports, and DICOM MPR visualizations. LAAO output includes mean landing-zone diameter measurements; TAVI output includes a perimeter-based aortic-annulus diameter that requires a manual measurement action. The application can also display output from FEops HEARTguide Simulation Application K214066.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes FEops HEARTguide ALPACA as a cloud-based device used in a service-based model in which FEops prepares the anatomical analysis and delivers results to clinicians through its web application. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Cloud-based Yes No, 3mensio is a Different, while the traditional software subject device is cloud-" … "The software is used in a service-based business model: the customer (clinician) provides the necessary input data, FEops prepares the anatomical analysis, and delivers the results to the customer.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The FDA packet describes a service-based cloud workflow, CT DICOM input, a web application, PDF reports, interactive 3D, and DICOM MPR outputs; the customer provides input data and FEops prepares and returns the anatomical analysis. Specific current PACS, RIS, EHR, interfaces, versions, hosting region, and local deployment are not established.
ACR AI Central provides an exact-submission model card for FEops HEARTguideTM, FEops HEARTguideTM ALPACA; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
22Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K223855 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-08 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: AI-CVD provides automated quantitative CT-derived anatomical and density measurements for clinician review, including calcium scores, cardiac and vascular measurements, lung and liver density, bone mineral density, and muscle/fat composition; it is opportunistic decision support, not diagnostic interpretation or risk prediction.
Authorized purpose: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.